ABSTRACT
Importance HIV transmission in Kazakhstan has increased among men who have sex with men (MSM) and transgender and nonbinary people who have sex with men (TSM), driven by low HIV testing rates.
Objective To determine if the PRIDE in HIV Care intervention had a community effect of increasing HIV testing among MSM and TSM in Kazakhstan.
Design We employed a stepped-wedge, cluster-randomized controlled trial with MSM and TSM community members recruited from three cities in Kazakhstan: Almaty, Astana, and Shymkent. We collected serial cross-sectional data where community members completed one assessment between 21 August 2018, and 30 March 2022.
Setting We collected data from 629 MSM and TSM among the study cities. Community respondents were recruited from real-world (e.g., NGOs, bars, clubs) or virtual sites (e.g., social media, apps) where MSM and TSM in each of the three cities were known to frequent.
Participants Eligibility criteria for community respondents were: (1) ≥18 years old; (2) identifying as male at any point in life or being assigned male at birth; (3) having consensual sex with another man in the past 12 months; (4) engaging in binge drinking (i.e., ≥5 drinks in a 2 hour period), illicit use of drugs, or both in the past 90 days; and (5) residing in one of the three study cities.
Intervention The PRIDE in HIV Care intervention is a theory-driven “crowdsourcing and peer-actuated network intervention” designed to amplify community members’ successes and resilience via “influencers” who can strengthen and impart benefit to their networks and community.
Main outcome measures Received an HIV test in the prior six months.
Results There was a statistically significant increase in odds of recent HIV testing for every additional month the intervention was implemented in a respondent’s city (AOR=1.08, 95% CI=1.05-1.12; p<.001).
Conclusions The PRIDE in HIV Care intervention appears to be efficacious in enacting a community wide increase—i.e., promoted HIV testing among those who did not go through the intervention itself—in HIV testing among MSM and TSM.
Trial Registration This trial is registered with clinicaltrials.gov (NCT02786615).
Funding National Institute on Drug Abuse (NIDA), grant number R01DA040513.
Question Does the PRIDE in HIV Care intervention exert a community effect of increasing HIV testing among men who have sex with men (MSM) and transgender and nonbinary people who have sex with men (TSM) in Kazakhstan?
Findings We employed a stepped-wedge, cluster-randomized controlled trial among three cities in Kazakhstan. There was a statistically significant increase in odds of recent HIV testing for every additional month the intervention was implemented in a respondent’s city.
Meaning The intervention increased HIV testing among MSM and TSM in Kazakhstan who had not directly received the intervention, providing support for a community-wide impact.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT02786615
Funding Statement
This research was supported by grant number R01DA040513 from the National Institute on Drug Abuse (NIDA). EAP was supported by the National Institute of Mental Health (grant numbers K01MH128117 and P30MH43520). AD was supported by NIDA (grant number K01DA044853). The funders had no role in the study design, data collection, data analysis, data interpretation, writing of this report, or decision to submit the article for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRBs of Columbia University and of Kazakhstan National University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author, Dr. Elwin Wu, upon reasonable request.
